Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. - Wikidata - wikimedia - TriplyDB

Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.

Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.

http://www.wikidata.org/entity/Q35812244

about

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer Treatment of advanced squamous cell carcinoma of the lung: a review Second-Line Therapy for Advanced NSCLC Review of the current targeted therapies for non-small-cell lung cancer Molecular pathology of non-small cell lung cancer: a practical guide.China Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)Epidermal growth factor receptor in non-small cell lung cancer NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population.Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.Molecular Testing of Lung Cancers Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.Novel agents in development for advanced non-small cell lung cancer.Lung injury and lung cancer caused by cigarette smoke-induced oxidative stress: Molecular mechanisms and therapeutic opportunities involving the ceramide-generating machinery and epidermal growth factor receptor.Activation of oncogenic pathways in idiopathic pulmonary fibrosis.Suitability of surgical tumor tissues, biopsy, or cytology samples for epidermal growth factor receptor mutation testing in non-small cell lung carcinoma based on chinese population.Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations.Lung cancer and lung injury: the dual role of ceramide Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors.Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes.Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction.A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada.Screening for germline EGFR T790M mutations through lung cancer genotyping.Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?Metastatic Squamous Cell Carcinoma Component from an Adenosquamous Carcinoma of the Lung with Identical Epidermal Growth Factor Receptor Mutations.Personalized choice of maintenance therapies in non-small-cell lung cancer A time to test, a time to treat.Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis New data on clinical decisions in NSCLC patients with uncommon EGFR mutations.First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.Prevalence and outcome of epidermal growth factor receptor mutations in non-squamous non-small cell lung cancer patients Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

P2860

Q24611043-BCE410B2-6A05-4F5E-9C53-055935F629E1 Q26771116-5815667D-EE19-47D2-AE63-3A289CADBB7F Q26775392-6B0A5B4B-7025-4B3A-BBF7-FA851E2BB93A Q27002398-EAA14CC1-65CD-4469-9581-D3192DCAD0ED Q27015079-A83500E6-9180-4CF9-943D-C70BBCEAB1DF Q27690919-E5075459-0492-41AD-B3AE-E94DE2938DFA Q28073920-BC03A6A7-B1FB-4139-BA3B-6FA9844782A2 Q28088636-43259DBF-3C77-418D-BEC5-01ED17E5CE4F Q28259999-DB31DD57-B650-4707-9DC1-16B89F0E8559 Q28392594-25FC7540-EA99-4219-966E-B2B50A329E54 Q30603151-B2451AC7-2974-42DB-A0BA-1AF5A37EE238 Q33682941-D48252A1-E672-4D0D-B7FA-6302B57BD904 Q33729715-AD265188-3B80-4119-9A11-011F78D315A9 Q33779181-D9707CCE-4CB4-45B6-A250-622E75A18ADD Q34041754-A76B2061-89BB-42C4-BE74-E0DAFA4777F8 Q34158993-22855AA9-D7D2-4AD6-9115-6FDC9FA5349D Q34266864-E7277B14-F8EC-43EB-9C60-1004A2B8173B Q34295696-16E8769A-E60B-4911-8EE3-0980B72DBB48 Q34389263-9E1B2E02-8DCF-4859-93D7-A1EB71304A40 Q34432733-0440B830-5485-4EF3-9205-1771E0DE071B Q34478556-12E50B1D-B864-4AD7-8FAB-AA30FF8A4FA4 Q35028752-DF059BCE-3216-4BB4-B836-1E74C04666BE Q35200585-4DA3CC8B-C766-4437-BC2A-FE0D4DD3A52D Q35207787-40F965A6-7A75-4F25-BAD4-BADB5606C3E8 Q35207876-68FB1891-C958-4C38-BE01-C53AA93E07EF Q35207885-CF648125-730E-48EA-B19A-2B9B878C6236 Q35718060-60076CFB-BAD0-4C1E-A525-5D676011672A Q35753530-E4272EBF-53B8-46BC-A6C1-289A5654782B Q35872687-187F126B-B11C-42D7-B686-A87AC7DE6352 Q35967349-9791032F-8F90-4FF6-9B3C-BB730FC88248 Q35986751-D36BD222-F8B0-423D-B429-A2F8789CB112 Q36031278-042FDF0D-4B25-41D6-8AB1-CE20F63C8769 Q36040632-EC44AF1F-C6C3-4AE3-A073-1A172B700A07 Q36042345-BC3A088B-8952-4433-8FD5-F09D7756B97D Q36151764-80F1C0AF-484C-4D45-9FA7-E09C9255CF36 Q36163279-32F2C52A-F783-4CC9-9136-08FA4BC87033 Q36215079-F4DD774A-BDD8-47CF-86F6-5DBC93D7EFE0 Q36283596-336FACD2-6B15-4072-A2BC-F43FEC78AA9E Q36330709-A4845744-6C40-47D5-9FB9-C88B48DD76DD Q36383418-0EE4143C-3167-4B01-ADBC-3AE95BF11057

P2860

Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.

http://www.wikidata.org/entity/Q35812244

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Incidence of EGFR exon 19 dele ...... ers with lung adenocarcinomas.

@ast

Incidence of EGFR exon 19 dele ...... ers with lung adenocarcinomas.

@en

type

label

Incidence of EGFR exon 19 dele ...... ers with lung adenocarcinomas.

@ast

Incidence of EGFR exon 19 dele ...... ers with lung adenocarcinomas.

@en

prefLabel

Incidence of EGFR exon 19 dele ...... ers with lung adenocarcinomas.

@ast

Incidence of EGFR exon 19 dele ...... ers with lung adenocarcinomas.

@en

P1433

Q35812244-691BCC3F-D028-4156-A22A-7DBBE00AB41A

P1476

Q35812244-559E40FA-9D61-42F2-B255-18CFD2303035

P2093

Q35812244-54571336-4568-412C-9229-D75EA7AC55A8

Q35812244-5C2461F5-8FF1-4D85-85D2-C73CBA406AD3

Q35812244-7C6ABD0E-4DFB-4D3E-9F5E-8B97086E5259

Q35812244-7DB7A84D-E8BB-4CE5-A448-4A8447574C2A

Q35812244-83CE2ECA-32AB-4F13-8C2C-570C5E8CD58D

Q35812244-C75CCA56-AFA1-43E3-9F79-7C33CC620D5B

Q35812244-C88D85E8-DB36-4585-AAD9-B7506A110568

Q35812244-CD0A108F-6D99-47E3-9D3A-4F909FDFB855

Q35812244-E5FE3A5D-A1C2-427C-8696-2E8133F41B34

P2860

Q35812244-057F87A2-9ECF-4FA6-BE66-DDB69DFDD7A1

Q35812244-14376A52-0FD8-4C92-8C81-4079C25BB482

Q35812244-1551B67D-C023-4EDA-BD21-4C07406A273C

Q35812244-202B8DC5-1178-4E99-8AC2-BF96D111CCD3

Q35812244-2EDC2392-A453-401C-B811-29922B364612

Q35812244-3DD35FCC-35C9-4003-8DF9-AF2A47A669D2

Q35812244-4AF00DC8-ABF0-44D2-A77F-71EF986BA430

Q35812244-68A8A618-A313-498B-BC8F-58DF67188672

Q35812244-772F8C6B-C839-4D39-930F-B7C504514D26

Q35812244-8B8EE141-D3E8-4537-B922-0F1A73CCCFDA

P304

Q35812244-F21ACF7C-A0C1-4456-9FF3-E1BAC182439C

P31

Q35812244-DD266638-193D-4CB6-8A79-333E8CEE449B

P356

Q35812244-1FE18FC9-1BB3-4CF5-A3B9-E788B4004A11

P407

Q35812244-46A70F4D-CA34-4819-9437-9B3D6B0DFEF4

P433

Q35812244-55929122-2573-4CC1-A64B-D7D6BDD2FC0B

P478

Q35812244-B47FB405-9672-4076-9DE7-2EDCFED849A2

P50

Q35812244-AD3B1811-146F-4285-B0CE-43BCB5F3DDBD

P577

Q35812244-DA4BF971-8C1C-4B30-88CE-93552BCD965C

P698

Q35812244-69B0B7B5-7A9D-4D00-989C-971F1F0BA1D0

P921

Q35812244-68108CF5-7007-43C9-844C-DF952E98183C

P932

Q35812244-E05C7E63-30E0-458E-A336-389C740191C5

P356

JCO.2010.32.6181

P1433

Journal of Clinical Oncology

P1476

Incidence of EGFR exon 19 dele ...... ers with lung adenocarcinomas.

@en

P2093

Camelia S Sima

http://www.w3.org/2001/XMLSchema#string

Gregory J Riely

http://www.w3.org/2001/XMLSchema#string

M Catherine Pietanza

http://www.w3.org/2001/XMLSchema#string

Mark G Kris

http://www.w3.org/2001/XMLSchema#string

Maureen F Zakowski

http://www.w3.org/2001/XMLSchema#string

Melissa L Johnson

http://www.w3.org/2001/XMLSchema#string

Sandra P D'Angelo

http://www.w3.org/2001/XMLSchema#string

Valerie W Rusch

http://www.w3.org/2001/XMLSchema#string

Vincent A Miller

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Detection of mutations in EGFR in circulating lung-cancer cells

Screening for epidermal growth factor receptor mutations in lung cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer.

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.

Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial

P304

2066-2070

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.32.6181

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21482987

http://www.w3.org/2001/XMLSchema#string

P921

P932

3296671

http://www.w3.org/2001/XMLSchema#string